Zimbabwe has turned down a major US healthcare agreement worth 367 million US dollars (£272m) over five years over the United States' demand for confidential data.
This rejection came to light following a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesman later explained that the US was seeking genetic material for research and commercial purposes but was unwilling to share the benefits from any future vaccines.
"We will now turn to the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for further dialogue to reach a agreement acceptable to all parties so the country's critical HIV treatment initiative can be sustained.
Broader Background
This development follows a comparable case in neighbouring Kenya, where a court halted a similar deal with the US following legal challenges were filed about the security of citizens' health data.
After returning to office last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed aid for the American government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government agreements to boost openness and responsibility.
According to reports, 16 African countries have to date signed similar agreements, representing more than $18.3bn in new funding.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation could have provided immense advantages for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Our nation was requested to provide its genetic material and health information over an extended period, without any equivalent promise of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Effectively, our country would provide the raw materials for medical research without any certainty that the resulting innovations would be available to our population should a new pandemic arise."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending frameworks already set up through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This framework is intended to ensure that when a nation provides its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to create them."
These objections regarding the US deal "are not meant as opposition to America," he added.
"We welcome ongoing dialogue with our US partners on how subsequent collaboration might be designed in a way that honours the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the government's concerns, but recommended that negotiations must proceed since a large portion of the country's HIV programmes relied on foreign aid.
"If technical issues arise, including those involving information security or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," the group said.
This impasse emphasises the complex challenges between receiving vital international aid and protecting local interests in an ever more data-driven world.